Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

(2023) Zobair M. Younossi et al.   HEPATOLOGY

Challenges and opportunities in NASH drug development

(2023) Stephen A. Harrison et al.   NATURE MEDICINE

Pattern recognition receptors in the development of nonalcoholic fatty liver disease and progression to hepatocellular carcinoma: An emerging therapeutic strategy

(2023) Chen Huang et al.   Frontiers in Endocrinology

Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/Smad3 signaling pathways

(2022) Eduardo E. Vargas-Pozada et al.   Annals of Hepatology

NAFLD‐related hepatocellular carcinoma: The growing challenge

(2022) Pir Ahmad Shah et al.   HEPATOLOGY

NLRP3 Inflammasome and Pyroptosis in Liver Pathophysiology: The Emerging Relevance of Nrf2 Inducers

(2022) Laura Hurtado-Navarro et al.   Antioxidants

Activation of the NLRP3 inflammasome by CCl4 exacerbates hepatopathogenic diet-induced experimental NASH

(2022) Eduardo E. Vargas-Pozada et al.   Annals of Hepatology

Caffeine Inhibits NLRP3 Inflammasome Activation by Downregulating TLR4/MAPK/NF-κB Signaling Pathway in an Experimental NASH Model

(2022) Eduardo E. Vargas-Pozada et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Diet-induced gut dysbiosis and inflammation: Key drivers of obesity-driven NASH

(2022) Gideon G. Kang et al.   iScience

NLRP3 inflammasome activation and cell death

(2021) Yi Huang et al.   Cellular & Molecular Immunology

Role of the Inflammasome in Liver Disease

(2021) Marcelle de Carvalho Ribeiro et al.   Annual Review of Pathology-Mechanisms of Disease

Models of nonalcoholic steatohepatitis potentiated by chemical inducers leading to hepatocellular carcinoma

(2021) Linda Vanessa Márquez-Quiroga et al.   BIOCHEMICAL PHARMACOLOGY

Mechanisms of Fibrosis Development in NASH

(2020) Robert F. Schwabe et al.   GASTROENTEROLOGY

Berberine Inhibits Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome Activation and Pyroptosis in Nonalcoholic Steatohepatitis via the ROS/TXNIP Axis

(2020) Weijian Mai et al.   Frontiers in Pharmacology

Role of pyroptosis in liver diseases

(2020) Abdullah Al Mamun et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis

(2020) Susanne Gaul et al.   JOURNAL OF HEPATOLOGY

Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin

(2020) Wenqi Yang et al.   LABORATORY INVESTIGATION

Dietary Niacin Intake Predicts the Decrease of Liver Fat Content During a Lifestyle Intervention

(2019) Katarzyna Linder et al.   Scientific Reports

Rebaudioside A administration prevents experimental liver fibrosis: an in vivo and in vitro study of the mechanisms of action involved

(2019) Sael Casas‐Grajales et al.   JOURNAL OF APPLIED TOXICOLOGY

Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug?

(2019) Moti L. Kashyap et al.   Journal of Clinical Lipidology

TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019

(2019) Dewidar et al.   Cells

Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature

(2018) Fahrettin Haczeyni et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Lipotoxicity and the gut-liver axis in NASH pathogenesis

(2018) Fabio Marra et al.   JOURNAL OF HEPATOLOGY

A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer

(2018) Takuma Tsuchida et al.   JOURNAL OF HEPATOLOGY

Mechanisms of NAFLD development and therapeutic strategies

(2018) Scott L. Friedman et al.   NATURE MEDICINE

Stevia Prevents Acute and Chronic Liver Injury Induced by Carbon Tetrachloride by Blocking Oxidative Stress through Nrf2 Upregulation

(2018) Erika Ramos-Tovar et al.   Oxidative Medicine and Cellular Longevity

Molecular pathways of nonalcoholic fatty liver disease development and progression

(2018) Fernando Bessone et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Quercetin reverses experimental cirrhosis by immunomodulation of the proinflammatory and profibrotic processes

(2017) Sael Casas-Grajales et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice

(2017) Auvro R. Mridha et al.   JOURNAL OF HEPATOLOGY

Coffee consumption prevents fibrosis in a rat model that mimics secondary biliary cirrhosis in humans

(2017) Jonathan Arauz et al.   NUTRITION RESEARCH

Relevance of the NLRP3 Inflammasome in the Pathogenesis of Chronic Liver Disease

(2017) Xiaoqin Wu et al.   Frontiers in Immunology

Niacin as antidyslipidemic drug

(2015) Ulrich Julius   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Nicotinic acid prevents experimental liver fibrosis by attenuating the prooxidant process

(2015) Jonathan Arauz et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease

(2015) Shobha H. Ganji et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease

(2013) Shobha H. Ganji et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease

(2010) Elisa Fabbrini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM